Navigation Links
Phase 2 Data for Ultra-Long-Acting Insulin Degludec Shows the Potential to Effectively Lower Blood Sugar, Including When Used Three Times a Week
Date:6/25/2010

ORLANDO, Fla., June 25 /PRNewswire-FirstCall/ -- Novo Nordisk today presented phase 2 proof-of-concept data for its investigational insulin degludec, an ultra-long-acting basal insulin, which demonstrated the potential to help achieve target glycemic control when used once daily or three times weekly. These data were presented at the 70th Scientific Sessions of the American Diabetes Association (ADA).(1)

These phase 2 studies showed that insulin degludec helped improve glucose control. In one study, after 16 weeks of treatment with insulin degludec, mean HbA1c reductions were similar across the once-daily and three-times-weekly insulin degludec groups (-1.3% and -1.5% respectively) and comparable to insulin glargine (-1.5%).(2)

In this study, 77% of patients treated with insulin degludec three times weekly did not experience any confirmed hypoglycemia (defined as low blood glucose levels or episodes that required assistance). This result was similar in the study arm using insulin glargine once daily. Of those patients using insulin degludec once daily, 92% did not experience any confirmed hypoglycemia. A formal statistical test was not possible due to low number of patients in this study (60-62 in each arm).

"Insulin degludec has shown the potential to help deliver improvements in glycemic control with less than one daily injection," said Mads Krogsgaard Thomsen, executive vice president and chief science officer at Novo Nordisk. "The low rate of hypoglycemia after once-daily insulin degludec administration, as well as the potential to be used three times weekly in people with type 2 diabetes will be further evaluated in our pivotal phase 3 trials in the BEGIN™ and BOOST™ programs."

Insulin degludec/insulin aspart (IDegAsp), a combination-insulin with insulin degludec and insulin aspart, is being tested in the BOOST™ program. It is being studied for its ability to provide the ultra-long-acting basal coverage of insulin degludec as well as a bolus boost to cover the meal coinciding with the injection. Phase 2 data presented at ADA showed that IDegAsp once daily brought the majority of patients to ADA-recommended glycemic targets (<7% HbA1c) without confirmed major hypoglycemia after 16 weeks of treatment.(3) In this proof-of-concept trial, there were 60 patients taking insulin glargine and 59 on IDegAsp with comparable glycemic control.

Novo Nordisk is exploring the clinical profile of insulin degludec and IDegAsp in one of the largest ever phase 3a clinical trial programs in the field of insulin therapy, BEGIN™ and BOOST™, with more than 10,000 patients.

Adverse events

The most common adverse events were headache, diarrhea and nasopharyngitis; and most were mild to moderate in severity.

About the mode of action

Insulin degludec is an investigational insulin molecule that has a distinct mode of action that provides a smooth and stable profile. The ultra-long clinical profile is derived from the soluble multi-hexamer formation and the continuous slow and stable release of insulin degludec monomers.(1)

Novo Nordisk is a global healthcare company with 87 years of innovation and leadership in diabetes care. The company also has leading positions within hemophilia care, growth hormone therapy and hormone replacement therapy. Headquartered in Denmark, Novo Nordisk employs more than 29,300 employees in 76 countries, and markets its products in 179 countries. Novo Nordisk's B shares are listed on the NASDAQ OMX Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk-us.com.

References

  1. Jonassen, I et al. Insulin Degludec is a new generation ultra-long-acting basal insulin with a unique mechanism of protraction based on multi-hexamer formation. Oral Presentation no. 39-OR, presented at the American Diabetes Association (ADA) Scientific Sessions 2010, Orlando, Florida. June 2010.
  2. Zinman, B et al. Insulin degludec, a new generation ultra-long acting insulin used once-daily or three times weekly in people with type 2 diabetes: Comparison to insulin glargine. Oral Presentation no. 40-OR, presented at the American Diabetes Association (ADA) Scientific Sessions 2010, Orlando, Florida. June 2010.
  3. Heise, T et al. Once-daily use of a new generation, ultra-long acting basal insulin with a bolus boost in insulin naive people with type 2 diabetes: Comparison with insulin glargine. Oral Presentation no. 34-OR, presented at the American Diabetes Association (ADA) Scientific Sessions 2010, Orlando, Florida. June 2010.


'/>"/>
SOURCE Novo Nordisk
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Lexicon Presents Data Describing LX4211 Positive Phase 2 Clinical Results and Novel Mechanism of Action for Type 2 Diabetes
2. Sinapis Pharma Commences Phase I Trial
3. Zydus Novel Orally Administered GLP-1 Agonist - ZYOG1 to treat Diabetes and Obesity Enters Phase I Clinical Trial
4. InteKrin Therapeutics to Present Phase 2b Clinical Data for Edema at the 2010 American Diabetes Association Annual Meeting
5. DURECT Reports Data From European Phase IIb Hysterectomy Study of POSIDUR(TM) (SABER(TM)-Bupivacaine)
6. Trius Therapeutics Obtains Special Protocol Assessment With FDA for Phase 3 Study of Torezolid Phosphate
7. Upsher-Smith Laboratories Announces Initiation of Phase III Clinical Trial of USL255 (Extended-Release Topiramate) for Adjunctive Treatment of Partial-Onset Epilepsy
8. MultiCell Hires Clinical Research Organization to Manage MCT-125 Phase IIb Clinical Trial
9. Updated Results from Phase 2 Trial Demonstrate Prolonged Hematologic Relapse-Free Survival of Micromets Blinatumomab in Patients with Acute Lymphoblastic Leukemia
10. Phase 3 Trial of Nexavar in First-Line Advanced Non-Small Cell Lung Cancer Does Not Meet Primary Endpoint of Overall Survival
11. Poniard Announces Final Data from Phase 3 SPEAR Trial of Picoplatin in Small Cell Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/31/2016)... -- The global biomaterials market is driven by ... deaths from chronic diseases. According to research report, "Global Biomaterials ... and Forecasts (2016-2021) - (By Value; By Material Type - ... Care); By Region-North America, Europe , APAC, ... , Italy , Japan ...
(Date:5/31/2016)... , May 31, 2016 ... Health Assembly zur Eliminierung von viraler Hepatitis    ... eine historische Verpflichtung eingegangen, virale Hepatitis bis 2030 ... World Health Assembly haben sich die Staaten ... viraler Hepatitis (Global Viral Hepatitis Strategy) zu verabschieden, ...
(Date:5/30/2016)... India , May 30, 2016 /PRNewswire/ ... market research report "Healthcare Biometrics Market by ... (Signature, Voice)), Multifactor, Multimodal), Application (Workforce Management), ... Forecast to 2021", published by MarketsandMarkets, the ... Million by 2021 from USD 1,182.6 Million ...
Breaking Medicine Technology:
(Date:5/31/2016)... ... ... day, adults often find themselves reaching for a cup of coffee, an energy drink, or ... instead is a cup of Matcha green tea. Matcha is a premium green tea powder ... from early June to mid-July, when the leaves are the most tender. , ...
(Date:5/31/2016)... ... 31, 2016 , ... Twenty years ago it was revolutionary: enabling the people ... the voices they hear. But this approach has proven transformative, both for people who ... gained credibility and now is used around the world, but it still lags in ...
(Date:5/31/2016)... ... 31, 2016 , ... Spartan Bioscience today introduced the Spartan ... convenience. , The Cube is exceptionally small—it takes up the space of a ... into any space, whether in a hospital, doctor’s office, or pharmacy. , The ...
(Date:5/31/2016)... CA (PRWEB) , ... May 31, 2016 , ... WaterField ... for digital-minded professionals, announces the waxed-canvas and leather Duo Dopp Kit , the ... waxed canvas or ballistic nylon, the Duo is smartly designed for Dad’s ...
(Date:5/31/2016)... ... May 31, 2016 , ... Phynd Technologies, Inc. announced recently the signing of ... TX and Shore Medical Center – Somers Point, NJ. The new clients range in ... demonstrating the breadth of Phynd’s solution and its interoperability. , Houston Methodist is a ...
Breaking Medicine News(10 mins):